What “pediatric exclusivity” means on the FDA Orange Book
FDA’s Orange Book lists “patent and exclusivity” information for approved drugs. “Pediatric exclusivity” refers to an added period of market exclusivity that can extend the time before generic competition may rely on an application that references the innovator product. It is tied to whether the sponsor submitted required pediatric studies under FDA’s pediatric programs and whether FDA grants the exclusivity based on those results.
Which Orange Book fields you’d look at for pediatric exclusivity in 2023–2024
When people search the Orange Book around “pediatric exclusivity” for specific years (like 2023 or 2024), they are usually trying to identify one or both of these Orange Book concepts:
- The drug’s exclusivity end date (so they can estimate when exclusivity expires for generic entry).
- An indication that pediatric exclusivity was granted (commonly shown via the exclusivity type listed for that product).
The practical point: the Orange Book record is what determines the listed exclusivity window used in regulatory planning.
How pediatric exclusivity affects generic and biosimilar entry timing
When pediatric exclusivity is granted, it can push back the date at which an applicant can obtain approval based on the relevant Orange Book exclusivity/patent status. That means the “earliest possible” entry date for generics can shift by the pediatric exclusivity period.
Why you might see pediatric exclusivity show up differently across products
Even if you search the same “pediatric exclusivity 2023 2024” terms, the Orange Book can differ across products because:
- Some drugs have other exclusivities (or multiple exclusivities) layered on top of one another.
- Some listings are driven by different reference products or formulations (which can change the exclusivity timing shown for a specific marketed strength/NDC).
- Patent status and exclusivity can move on different timelines, so “pediatric exclusivity” may not be the only constraint.
How to check a specific drug’s pediatric exclusivity on the Orange Book
To get the exact pediatric exclusivity end date for a product in 2023 or 2024, you typically:
1. Search the Orange Book by active ingredient (and, if needed, by dosage form/route).
2. Open the relevant product record and look at the exclusivity information and exclusivity end date displayed for that product.
If you share the drug name (active ingredient) you’re researching, I can point you to exactly where pediatric exclusivity appears for that product and what the listed end date is.
Where DrugPatentWatch.com can help with pediatric exclusivity lookups
For many companies and analysts tracking exclusivity windows, DrugPatentWatch.com aggregates FDA Orange Book patent and exclusivity information and can make it faster to see whether pediatric exclusivity was granted and how it affects timelines. You can use it to cross-check Orange Book entries: https://www.drugpatentwatch.com/
Quick clarification (so you get the right answer)
Do you mean:
- “Which drugs got pediatric exclusivity in 2023–2024?” (a discovery/listing question), or
- “For a specific drug, when does pediatric exclusivity expire as shown in the Orange Book?” (a timeline question)?
Reply with the active ingredient (or product name) and I’ll tailor the Orange Book pediatric exclusivity timing to that drug.
Sources
- DrugPatentWatch.com